The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Cyclosporin promotes neurorestoration and cell replacement therapy in pre-clinical models of Parkinson's disease.

Author

  • Anna Tamburrino
  • Madeline J Churchill
  • Oi Wan Wan
  • Yolanda Colino Sanguino
  • Rossana Ippolito
  • Sofie Bergstrand
  • Daniel Wolf
  • Niculin J Herz
  • Michelle D Sconce
  • Anders Björklund
  • Charles K Meshul
  • Mickael Decressac

Summary, in English

The early clinical trials using fetal ventral mesencephalic (VM) allografts in Parkinson's disease (PD) patients have shown efficacy (albeit not in all cases) and have paved the way for further development of cell replacement therapy strategies in PD. The preclinical work that led to these clinical trials used allografts of fetal VM tissue placed into 6-OHDA lesioned rats, while the patients received similar allografts under cover of immunosuppression in an α-synuclein disease state. Thus developing models that more faithfully replicate the clinical scenario would be a useful tool for the translation of such cell-based therapies to the clinic.

Department/s

Publishing year

2015-12-14

Language

English

Publication/Series

Acta Neuropathologica Communications

Volume

3

Issue

1

Document type

Journal article

Publisher

BioMed Central (BMC)

Topic

  • Neurosciences

Status

Published

ISBN/ISSN/Other

  • ISSN: 2051-5960